TORONTO, Aug. 2 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. today announced an agreement with JUSTE S.A.Q.F. (“JUSTE”), a leading supplier of in-vitro diagnostic technologies, medical devices, and pharmaceuticals in Spain, to sell and distribute Spectral’s EAA(TM) Endotoxin Activity Assay.
Spectral has been actively developing a strong network of top-tier distributor relationships on a regional basis in Europe, where the potential for early growth of EAA(TM) sales is strong. JUSTE, which has an extensive network of sales and support in Spain, and Spectral will work jointly to maximize sales of the EAA(TM). JUSTE has initially placed a significant order for tests and instrumentation to ensure rapid introduction of the product into the Spanish market.
“We are very pleased to announce this new relationship with JUSTE,” stated Dr. Paul Walker, President and CEO of Spectral. “Their dominant presence in Spain will put EAA(TM) in the best possible position to capture this important market. Spectral believes that working with strong local distributors that have close ties to clinicians and hospitals will significantly increase the rate of the uptake of EAA(TM).”
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Currently products include Spectral’s rapid West Nile Virus (WNV) assay and its FDA approved rapid diagnostic for sepsis (the Endotoxin Activity Assay) as well as a range of other biological reagents. Spectral’s common shares are listed in the Toronto Stock Exchange under the symbol “SDI”.
JUSTE, S.A.Q.F. is a company which researches, develops and distributes pharmaceutical, diagnostic and medical device products. Its main business areas are the distribution and commercialization of drugs (both for hospital and prescription use) and contrast media agents. JUSTE, through Juste International subsidaries, is present in Central America, as well as in Argentina, Mexico and Brazil via Justesa Imagen affiliates. Revenues of Juste Group in 2005 were 121 Million Euros.
Information in this news release that is not current or historically factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, the future outlook of Spectral and anticipated events or results are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
Spectral Diagnostics Inc.
CONTACT: At: Spectral Diagnostics Inc., Dr. Paul M. Walker, President andCEO, (416) 626-3233 Ext. 2100
